← Leaderboards
Patrick Alexander Ott
Dana-Farber Cancer Inst
$3,127,186
Attributed
$3,127,186
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $627.9K · FY2018–23$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,127,186 · 1
By mechanism
R01$3,127,186 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Kai W Wucherpfennig$37,935,181
- Camila Robles-Oteiza$468,821
- Panagiotis Konstantinopoulos$4,290,380
- Frank S Hodi$11,927,265
- Tracy T Batchelor$27,819,477
Others in their field
Other Emerging Leaders on “Clone Cells”
- Frederic Geissmann · Sloan-Kettering Inst Can Research$7,908,863
- Ali Hassan Ellebedy · Washington University$6,293,521
- Kamila Naxerova · Massachusetts General Hospital$5,724,979
- James Amos-Landgraf · University Of Missouri-Columbia$5,263,805
- Joseph Christopher Mudd · Tulane University Of Louisiana$4,281,250
- Wa Xian · University Of Texas Hlth Sci Ctr Houston$4,191,801
Research focus
Clone CellsCentral ToleranceClinical TrialsCd8-Positive T-LymphocytesAlgorithmsAdoptedCellsCheckpoint InhibitionAntigensAgonistAnti-Pd-1Anti-Pd1 TherapyArchitectureAntibodiesAftercareAvidityAdvanced DiseaseBindingBiopsyBloodAntigen-Specific T CellsCancer PatientCancer VaccinesCombinatorial
Grant awards (5)
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition$615,390
R01 · FY2023 · CA · contact PI
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition$627,949
R01 · FY2022 · CA · contact PI
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition$627,949
R01 · FY2021 · CA · contact PI
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition$627,949
R01 · FY2020 · CA · contact PI
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition$627,949
R01 · FY2018 · CA · contact PI